现代妇女（医学前沿）
現代婦女（醫學前沿）
현대부녀（의학전연）
Modern Women（Frontiers of Medicine）
2014年
11期
110-112
,共3页
唐建琼%黎艳丽%岳小娅%陈蓓蕾%高静%董昌虎
唐建瓊%黎豔麗%嶽小婭%陳蓓蕾%高靜%董昌虎
당건경%려염려%악소아%진배뢰%고정%동창호
多发性骨髓瘤%COMP方案%沙利度胺%疗效评价
多髮性骨髓瘤%COMP方案%沙利度胺%療效評價
다발성골수류%COMP방안%사리도알%료효평개
multiple myelom%COMP regimen thalidomide%curative effect evaluation
目的：观察COMP (cyclophosphamide, C；oncovin, O；melphalan, M；prednisone, P)方案（环磷酰胺、长春新碱、马法兰、泼尼松）联合小计量沙利度胺治疗多发性骨髓瘤（multiple myelom, MM）的临床疗效和不良反应。方法33例MM患者均采用COMP方案,同时整个病程中给予沙利度胺100～200mg/d。至少3个疗程后评价总疗效。结果总有效率（overall response rate, ORR）为87.88%（29/33），其中完全缓解（complete remission, CR）42.42%(14/33),部分缓解（partial remission, PR）39.39%（13/33）,进步（improve, I）12.12%(4/33),无效(no remission, NR)6.06%(2/33)，29例患者不良反应轻微。患者治疗前后血红蛋白水平及骨髓中浆细胞比例差异均有统计学意义（均P＜0.05）。结论COMP方案联合小剂量沙利度胺治疗MM患者有效率高,能有效提高生存时间,且不良反应较少，是治疗MM的有效方案。
目的：觀察COMP (cyclophosphamide, C；oncovin, O；melphalan, M；prednisone, P)方案（環燐酰胺、長春新堿、馬法蘭、潑尼鬆）聯閤小計量沙利度胺治療多髮性骨髓瘤（multiple myelom, MM）的臨床療效和不良反應。方法33例MM患者均採用COMP方案,同時整箇病程中給予沙利度胺100～200mg/d。至少3箇療程後評價總療效。結果總有效率（overall response rate, ORR）為87.88%（29/33），其中完全緩解（complete remission, CR）42.42%(14/33),部分緩解（partial remission, PR）39.39%（13/33）,進步（improve, I）12.12%(4/33),無效(no remission, NR)6.06%(2/33)，29例患者不良反應輕微。患者治療前後血紅蛋白水平及骨髓中漿細胞比例差異均有統計學意義（均P＜0.05）。結論COMP方案聯閤小劑量沙利度胺治療MM患者有效率高,能有效提高生存時間,且不良反應較少，是治療MM的有效方案。
목적：관찰COMP (cyclophosphamide, C；oncovin, O；melphalan, M；prednisone, P)방안（배린선알、장춘신감、마법란、발니송）연합소계량사리도알치료다발성골수류（multiple myelom, MM）적림상료효화불량반응。방법33례MM환자균채용COMP방안,동시정개병정중급여사리도알100～200mg/d。지소3개료정후평개총료효。결과총유효솔（overall response rate, ORR）위87.88%（29/33），기중완전완해（complete remission, CR）42.42%(14/33),부분완해（partial remission, PR）39.39%（13/33）,진보（improve, I）12.12%(4/33),무효(no remission, NR)6.06%(2/33)，29례환자불량반응경미。환자치료전후혈홍단백수평급골수중장세포비례차이균유통계학의의（균P＜0.05）。결론COMP방안연합소제량사리도알치료MM환자유효솔고,능유효제고생존시간,차불량반응교소，시치료MM적유효방안。
Objective To investigate the clinical efficacy and adverse reactions of COMP (cyclophosphamide, C; oncovin, O; melphalan, M;prednisone, P) regimen combined with low dose thalidomide in the treatment of multiple myeloma (MM). Methods 33 patients with MM used COMP regimen. At the same time, thalidomide is given 100~200 mg/d in the whole course. The efficacy was evaluated after 3 cycles of treat-ment. Results The overall response rate (ORR) was 87.88%,including complete remission (CR) 42.42%(14/33), partial remission (PR) 39.39%(13/33), improve (I) 12.12%(4/33), no remission (NR) 6.06% (2/33), 29 patients have mild adverse reactions. Before and after treatment,the discrepancy of plasma hemoglobin level and the proportion of plasmocyte in marrow was documented, and a value of P<0.05 was considered statistically significant. Conclusion COMP regimen combined with low dose thalidomide in treatment of MM has many advantages such as 1ess side-effects,good tolerance,convenient administration and significant curative effects, so it should be recommended in clinical works.
